Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
Frontiers in Oncology · 04.01.2023 · 12
DOI: 10.3389/fonc.2022.1077436 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 04.01.2023. Verfasst von Zong-Han Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic lymphocytic leukemia (CLL) has become one of the most common hematological diseases in western countries, with an annual incidence of 42/100,000. Conventional chemotherapy and targeted therapeutic drugs showed limitations in prognosis or in efficiency in high-risk patients. Immunotherapy represented is one of the most effective therapeutic approaches with the potential of better effect and prognosis. Natural killer (NK) cells are good options for immunotherapy as they can effectively mediate anti-tumor activity of immune system by expressing activating and inhibiting receptors and recognizing specific ligands on various tumor cells. NK cells are critical in the immunotherapy of CLL by enhancing self-mediated antibody-dependent cytotoxicity (ADCC), allogeneic NK cell therapy and chimeric antigen receptor-natural killer (CAR-NK) cell therapy. In this article, we reviewed the features, working mechanisms, and receptors of NK cells, and the available evidence of the advantages and disadvantages of NK cell-based immunotherapies, and put forward future study directions in this field.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
- Department of General Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
- Department of Gastrointestinal Nutrition and Surgical Surgery, The Second Affiliated Hospital of Jilin University, Changchun, Jilin, China.
Zitieren
APA
Wang, Z. H., Li, W., Dong, H., & Han, F. (2023). Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1077436
Vancouver
Wang ZH, Li W, Dong H, Han F. Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia. Frontiers in Oncology. 2023;12. doi:10.3389/fonc.2022.1077436
BibTeX
@article{Wang2023,
author = {Wang, Zong-Han and Li, Wei and Dong, Hao and Han, Fujun},
title = {Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia},
journal = {Frontiers in Oncology},
year = {2023},
volume = {12},
doi = {10.3389/fonc.2022.1077436}
}
EUVIMED